Member Info for TruroTrader

Just re-read the CMD and I reckon this is the best position we've been in since I first bought shares in Vialogy in 2008. I'd prefer to see how this goes now that we've got established in the states. Would be good if the stateside revenue was separate in the full accounts as we know it's doubled, but not from what. The first quarter update should be good.
There's every chance that if the second super-lab comes on stream fairly quickly we will better the '21/'22 revenue anyway.

I was basically encouraged. A lot of info re two of the main products. State side is already into one of the super labs and working on another re NIPT. The Ex5 takeover is paying real service dividends compared to what we paid for it. If the SP does not rise to much this week I will top-up.

Solid growth that looks to be repeated in this current year. I don't think I've ever held in a company before that had such a visible upward trajectory. I just love the largely fixed cost base and the way the the bulk of the revenue increase falls to the bottom line. Now the only question is do we get a maiden divi this financial year or next? Decisions decisions always decisions !!!

We've got a few irons in the stateside fire but this one benefits from a two-way potential. It's been worked on for 9 months so it should hit the ground running and produce good margin revenue quickly. V encouraging - roll on tomorrow.

As CooperD says this is a route out of Covid revenues. The highlight of the CMD will be for me Scott Sargent's take on North America. This is another source of revenue there that has the full year to develop. Dare to Dream?

Thanks for the link institution. Didn't realise the 10 II's had some 350 Mill shares between them. I think that's probably high in both II's and shares for a company not yet at break-even. YGEN must be doing something right I guess.

Looking forward to CMD and for me the highlight will be Scott Sargent's take on North America this has to be key for YGEN. in my book. Cheers.

Hi Investor, read the article - can't say I understood it all though!! The Virtual Tumor product is protected by both patents and is also trade marked. We do seem to have a unique offering in an exponential growth area that has only started to become a practical reality in the last decade or so.

I don't think that PYC's potential is actually appreciated by the current MC. You would think that to work with much bigger pharma companies over several years demonstrates our unique advantage. Got a feeling that PYC's time is about to come.

The Trading update RNS says 'there expected' week commencing 25th April.

Congratulations on your prophecy MonkeyTennis1. PS - Got your lottery numbers handy???

I echo dactions thanks Blurill. It does seem a little odd to me but there must be some sort of business case perhaps in that any compo could fund both businesses? I do have to say that I would have preferred Fox in profit before any diversification but hey - what do I know.? Thanks again.

Couldn't access anything bluerill - any other info please?

Oh well - it was nice while it lasted!!

Woo-Har A bid of double figures. Roll on the CMD

Merck KGaA is a major player. It is perhaps testament to our product that PYC has been a consistent customer/client for many years and Virtual Tumor has attracted increased their spending with us over those years. In the December RNS Millen said that we were engaged with them on a number of their key clinical programs. Apparently this area is being seen as increasingly important in general to PYC. See the 10th of May Trading update. PYC is looking to move from pre-clinical work to more high value clinical projects. Couple this with the commercial partnership/business projects and growth looks good.

It seems to me then that this relationship will run and run and be increasingly valuable. Not only that but with other business contracts now being named (which wasn't always the case) our credence is growing and so is our revenue. Good times coming I think. Finally I'm really looking forward to reading the year end trading update - hopefully in July.

Many thanks for the 2 links niky - The Spanish turbine blades were apparently some 4 years in testing which was news to me. EDF has been testing, I think, for a couple of years now so we're still some way. Covid probably slowed down both of them. However as we appear to be testing for both steam with EDF and selling gas to Spain we therefore have a foot in both turbine camps and this could be a faster growth potential than aerospace! I think the revenue will be broken down in reports so the figures will be interesting. Cheers.

There is definitely a different feel to this company in the last two or three years or so. The day to day contract stuff is rising and we have three longer term commercial trials/contracts on the go. I guess the most obvious to increase revenue is the VAL one. I think the company has done well to keep the cost base down in spite of the rising headcount and have just done a small 1K top- up to benefit from the rising SP as revenue starts to rise and inevitably profits will follow.

It's quite all right share4 - no need to apologise for not understanding my post.

Re-read my post share4 and then comprehend it. You ask nonsensical and foolish questions. You might need to look up 'guess' in a dictionary.

Thanks invester1978. Good to see positive well constructed posts on here. Puts a lot of thoughtful background on our current situation which I for one think is in the best position we have ever been in. My guess is that next financial year we will break into profit, which, if the commercial deal with VAL comes through could be meaningful. Thanks again.

Hi john. Perhaps a little harsh in places? CG was no expert when Fox started but without the covid-19 travel bans and rocketing transport costs we could have been in profit by now irrespective of the Malesheva malarkey . He got Fox up and running and also got some experienced management in.

The new NED is no lightweight and in the RNS Andrew Allner the Chairman, commented: "We are pleased to welcome Sir Mark to the Board and look forward to leveraging his wealth of experience. This appointment comes at an important time for the Company and the Board looks forward to updating the market on progress made between now and the end of the year."

Well I guess suspension is important! However there is a plan which might be just a little better than one of Clarkson's! My average is now 1.49 so we could both be in with a decent profit particularly as shareholders are protected. Thank you Chris Gilbert and thanks to dactions and sailorgirl for their information .